Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacturing, marketing, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus for immunosuppressants therapeutic segment; temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix for oncology therapeutic segment; mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, amphotericin B, and nystatin for anti-fungal therapeutic segment; and lovastatin, pravastatin sodium, and enzymes for other applications. In addition, it provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for CONCORDBIO
Revenue projections for CONCORDBIO

With CONCORDBIO's revenue expected to be lower than the previous year, investors may become cautious. Declining revenues often negatively impact the bottom line, reducing profitability and raising concerns among investors about the company's ability to maintain strong financial performance moving forward.

Financial Ratios:

currentRatio 7.394000
forwardPE 30.470194
debtToEquity 0.115000
earningsGrowth -0.370000
revenueGrowth -0.241000
grossMargins 0.656960
operatingMargins 0.303570
trailingEps 24.820000
forwardEps 42.165800

CONCORDBIO's current ratio of 7.394 highlights the company's solid liquidity, indicating that it can easily service its short-term debt. CONCORDBIO's ample cash reserves and current assets ensure that the company is well-positioned to meet its immediate financial liabilities.
CONCORDBIO's low growth in both earnings and revenue indicates the company's profits may decrease. This trend could signal a downturn in financial performance, suggesting that CONCORDBIO might struggle to maintain its current profit levels.
With positive gross and operating margins, CONCORDBIO demonstrates strong profitability. This reflects the company's ability to manage costs and maintain healthy profits, showcasing effective operational efficiency and financial stability.
Concord Biotech Limited's forward EPS surpassing its trailing EPS signals projected growth in profitability, with the company expected to perform better this year. This forecast suggests that Concord Biotech Limited's earnings will improve compared to the previous financial year, highlighting optimism in its financial outlook.

Price projections:

Price projections for CONCORDBIO
Price projections for CONCORDBIO

Concord Biotech Limited's price has consistently hovered near the lower end of price projections. This trend suggests that the stock is underperforming relative to analyst expectations, indicating a potential lack of momentum for upward movement in the near future.

Recommendation changes over time:

Recommendations trend for CONCORDBIO
Recommendations trend for CONCORDBIO


A recent buy bias from analysts toward CONCORDBIO may inspire confidence in investors, who could view the stock as a promising investment. This positive sentiment suggests that CONCORDBIO might be an appealing option for those looking to grow their wealth through stock market investments.